ABSTRACT This study was undertaken to understand how Lentinula edodes modulates in vivo mutagenesis induced by alkylating agents in bone marrow and peripheral blood as described in our previous article. Male Swiss mice were pretreated for 15 consecutive days with aqueous extracts prepared from L. edodes, after which, the number of circulating blood cells, normal erythroid bone marrow cell cycling, and phagocytosis of micronucleated reticulocyte (MNRET) and activation of spleen macrophages were assessed. The results indicate that the antimutagenicity seen in bone marrow and peripheral blood is exerted by distinct compounds with different actions. The antimutagenic effect in bone marrow is exerted by compounds subject to degradation at deep-freeze storage temperature of -20°C. On the other hand, compounds responsible for antimutagenicity in peripheral blood are not subject to degradation at -20°C. The results also indicate that the antimutagenic action in peripheral blood leading to the reduction of circulating MNRET occurs in the spleen primarily through a phagocytic activity due to higher macrophage numbers and probably not due to the enhanced activation state of individual cells.
INTRODUCTION D
uring the past 20 years, particular attention has been directed to the study of antimutagenic compounds. Interest in these compounds also arises from the possibility of having systems that provide an accurate indication of the antimutagenic potential of a compound within a short period of time. Various compounds have been found to have antimutagenic properties, and their number continues to grow. The primary objective of the use of animal models in the antimutagenicity field is to acquire pharmacological information by taking into account absorption, distribution, metabolism, and excretion. However, although we have positive indications concerning antimutagenic properties, it is difficult to obtain a true understanding of the mechanisms involved because it is often unclear whether a specific effect is the result of a single mechanism or a combination of different mechanisms. 1 Adding more complexity to comprehending the mode of action related to the whole body approach in chemoprevention research, many complex dietary mixtures have been evaluated for their intervention in human carcinogenesis. However, extensive laboratory studies indicate that even though dietary constituents (complex mixtures) are composed of several mutagens/carcinogens as well as antimutagens/ anticarcinogens, intervention studies using specific complex food items show more effectiveness in terms of cancer reduction or increased longevity than do single compounds. 2 Interest in using mushrooms and/or mushroom extracts as dietary supplements is based on theories that they enhance immune function and promote health. In fact, several reports describe the effectiveness of mushrooms against the promotion and progression stages of carcinogenesis, demonstrating that complex mixtures may have additional effects improving the prevention of cancer. 3 Thus, in the same way, wholemushroom extracts containing different compounds could also interfere with the onset of mutation (initiation stage) in different ways, minimizing its potentially adverse consequences.
In 2001, our workgroup showed that an aqueous extract prepared from a fresh Lentinula edodes mushroom (LE 96/17) significantly reduced the induction of primary DNA damage in peripheral blood leukocytes as well as the mutagenicity induced in bone marrow and peripheral blood of mice. 4 Thus, assessing some different possibilities and using the same in vivo system, this study investigated how Lentinula edodes (Berk.) Pegler [ = Lentinus edodes (Berk.) Singer] modulates the mutagenicity induced by alkylating agents in vivo as previously reported.
MATERIALS AND METHODS

Animals
Male Swiss mice aged 7-8 weeks (35-40 g body weight) were obtained from the breeding colonies of the Animal Center, UNICAMP. The animals were kept in plastic cages, in an experimental room under controlled conditions of temperature (23 -2°C), humidity (50 -10%), 12-h light/12-h dark cycle, and ad libitum access to food and water.
Chemicals
The alkylating agents N-ethyl-N-nitrosourea (ENU; CAS No: 759-73-9; Sigma), dissolved in a phosphate buffer (pH 6.0), or cyclophosphamide (CP; CAS No: 50-18-0, Genuxal; Asta Médica), dissolved in 0.9% NaCl, were used to induce mutations in mouse hematopoietic cells.
Mushroom
Dried powder of the L. edodes mushroom was provided by the Agronomic School of Sciences. The mushroom (strain LE 96/17), produced in 2002, was kept in plastic bags and wrapped in thick paper to provide protection from light and subsequently stored at a deep-freeze temperature of -20°C until 2004. Consequently, all experiments in this study were carried out with the stored mushroom. Before storing the fresh dried powder mushroom (2002), we confirmed its antimutagenic potential (P < .01) using the in vivo bone marrow micronucleus test (MNT) against ENU chemically induced mutagenesis (results not shown).
Mushroom aqueous extracts L. edodes aqueous extract (2.5%) was prepared using 5 g of powdered mushroom added to 200 mL of filtered water (extract 1), while L. edodes aqueous extract 2 (5%) was prepared using 10 g of powdered mushroom added to 200 mL. Extracts were warmed to 60°C, and the temperature was maintained (thermometer) for 15 min before filtering. The filtered extract was kept in a freezer until use. After filtering, the total amount of mushroom compounds in 0.6 mL was about 0.015 g and 0.03 g for extracts 1 and 2, respectively. A volume of 0.6 mL was administered per rodent per day during the entire experimental period. The aqueous extracts used in this study were prepared from L. edodes powder stored for 2 years at a deep-freeze temperature of -20°C.
Micronucleus test
The MNT was conducted according to the methods described by MacGregor et al. 5 for bone marrow, and by
Hayashi et al. 6 for peripheral blood. The number of micronucleated cells was determined by counting 1000 polychromatic erythrocytes (PCEs) and 1000 reticulocytes (RETs) per animal. Slides were scored blindly using a light microscope with a 100· immersion objective for PCEs, and a fluorescent microscope for RETs, using a combination of a blue excitation filter (e.g., 488 nm) and a yellow to orange barrier filter (e.g., 515 nm long pass) and a 40· objective. The percentage of reduction in the micronucleated frequency after treatment with mushroom extracts 1 and 2 were calculated according to Manoharan and Banerjee 7 and Waters et al. 8 
Blood cell analysis
Red blood cell counts were performed using a hematology analyzer. White blood cell counts were performed on blood smears stained with Leishmann (Merck).
Phagocytic activity of spleen cells
To determine the effects of the L. edodes mushroom on the phagocytosis of micronucleated reticulocyte (MNRET) by spleen cells, mice were pretreated with L. edodes extract 1 (by gavage) for 15 days before intraperitoneal (i.p.) CP (50 mg/kg) administration. Animals were subsequently sacrificed in a CO 2 chamber 6 or 12 h after i.p. administration. Spleen cell suspensions were obtained by passing individual spleens through a stainless steel tissue sieve with a 5 mL cold medium (RPMI 1640; Gibco). Small cell clumps were broken down to single-cell suspensions by gentle pipetting. One hundred microliters of the single-cell suspension was placed immediately in the center of an acridine orange (AO) precoated glass slide and covered immediately with a 24 mm · 40 mm coverslip. The slides were kept in a freezer until analysis.
Preparation of AO-coated glass slides
AO was dissolved in distilled water at a concentration of 1 mg/mL. Next, 40 lL of this extract was placed on a preheated (about 70°C) clean glass slide and spread with a glass rod using a back and forth motion, and the slides were then air-dried. The AO-coated glass slides were stored in a dry place at room temperature until use. 6 
Phagocytosis analysis using fluorescent microscopy
The combination of a blue excitation filter (e.g., 488 nm) and a yellow to orange barrier filter (e.g., 515 nm long pass) should be used for microscopic analysis of slides. Before scoring, slides should be allowed to stain for a few hours overnight to allow cells to settle and to maximize staining. A suitable region of the slide should be selected with a lowpower objective before the start of phagocytosis scoring. 
Assay for spontaneous release of hydrogen peroxide
Hydrogen peroxide (H 2 O 2 ) release by spleen macrophages was determined according to Pick and Mizel. 9 Briefly, spleen macrophages were collected as described above for determination of the phagocytic activity, and plated on 96-well flat-bottom microculture plates at a final concentration of 2 · 10 6 cells/mL (100 mL/well); adherent cells were grown for 24 h without any stimulus. The culture supernatants were removed for further nitric oxide (NO) determination, and adherent cells were used for H 2 O 2 determination. The phenol red reagent (100 lL) containing 140 mM NaCl, 10 mM K 2 HPO 4 , 5.5 mM dextrose, and 5.5 mM horseradish peroxidase was added to wells, and the adherent cells were further incubated for 1 h at 37°C in a humidified chamber (5% CO 2 in air). The reaction was stopped by addition of 10 lL of 1 N NaOH and the absorbance was measured at 620 nm, using an automatic enzyme immunoassay reader.
Assay for spontaneous release of NO NO release by spleen macrophages was determined based on the Griess reaction. 10 As described above, the supernatants of adherent cell cultures were collected after 24 h and mixed with 100 lL of Griess reagent (0.1% N-1-naphthylethyl-enediamine + 1% sulfanilamide in 5% H 3 PO 4 ). After 10 min, absorbance was measured at 540 nm using an automatic enzyme immunoassay reader.
Statistical methods
The MNT data were evaluated statistically by the chisquare test. 11 The numbers of hematopoietic blood cells were compared by analysis of variance on Ranks, followed by the Dunn's test using SPSS software (version 1.0) for Windows. Comparisons of H 2 O 2 and NO production were carried out with the Kruskal-Wallis test using MINITAB software (version 14) . P values less than .05 were considered statistically significant.
RESULTS
Influence of storage on L. edodes antimutagenic effect Table 1 shows the effect of L. edodes after 2 years of storage at deep-freeze temperature (-20°C) on the frequencies of micronucleated polychromatic erythrocytes (MNPCEs) and MNRETs induced chemically by ENU (50 mg/kg), in bone marrow and in peripheral blood of mice. The results indicate that after storage, L. edodes extract did not reduce the frequency of bone marrow MNPCEs induced by ENU, but that the bioactive compounds responsible for the antimutagenic activity in peripheral blood caused a significant decrease in MNRET frequency. These findings indicate that antimutagenic effects seen in bone marrow and peripheral blood are exerted by compounds with different modes of action and a very different chemical stability.
Influence of L. edodes on normal cell cycling in bone marrow
The data in Table 2 suggest that the antimutagenic effect of L. edodes extract are not due to an influence on normal cell cycling since there was no delay or acceleration when there was a maximum reduction in MNRET in the blood stream in the treated groups versus the positive control. The results also show that there is a statistically significant difference when both treated groups are compared to the positive control; however, a comparison between the two treated groups (L. edodes extract 1 and 2) at the same sampling time indicated that there was no significant difference in the antimutagenic effect with dosages of 5 or positive control. ***Significantly different from positive control (P < .001). n, number of animals; MNPCEs, micronucleated polychromatic erythrocytes; MNRETs, micronucleated reticulocytes; ENU, N-ethyl-N-nitrosourea. Table 2 is that the reduction in MNRET frequency takes place by the first sampling time, indicating that the antimutagenic action occurs rapidly within the first 24 h after ENU administration. Table 3 presents the effect of treatment with L. edodes extracts on the number of circulating blood cells. The results indicate that the number of red blood cells determined in the treated group was not statistically different from that of the nontreated rodents. However, there was a significant increase in the relative number of monocytes observed in the blood smears. We also observed a biological effect related to the relative number of neutrophiles, although not statistically significant. Table 4 shows the effect of L. edodes extract 1 on the frequency of spleen cell phagocytosis in mice. A comparison between the positive control and treated group clearly indicates that the antimutagenic effect of L. edodes toward MNRET in peripheral blood was due in large part to the increased spleen cell phagocytosis of MNRET, which was equally significant at 6 and 12 h (P < .001) after micronucleus induction with CP. Figures 2 and 3 show that even though the spleen phagocytic activity was greatly increased by L. edodes pretreatment, the production of H 2 O 2 and NO from macrophages was comparable to the control value.
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DISCUSSION
In our previous article, 4 we reported that an aqueous extract obtained at 60°C from L. edodes fruiting bodies (strain 96/17) modulates the mutagenic effect induced chemically by CP and ENU in bone marrow PCEs as well as in peripheral blood RETs. That study also gave us an indication of one of the possible antimutagenic actions. The use of the comet assay with peripheral blood leukocytes indicated that positive control. Significantly different from positive control (*P < .05; **P < .01; ***P < .001). pretreatment with L. edodes significantly diminished the primary DNA damage induced by ENU. Consequently, it is possible that a general protection related to this reduction in DNA damage could also have affected bone marrow proerythroblasts contributing to a decrease in the frequency of MNPCE and MNRET in the treated groups.
In 2002, we received a new batch of (LE 96/17) to extend our investigation of the mode of action of the antimutagenic effect exerted by L. edodes extract. An evaluation carried out in the same year together with a subsequent one performed after 2 years of storage at -20°C gave us a second indication of active compound(s) acting at very distinguishable levels (Table 1) . Interestingly, while the antimutagenic effect in bone marrow was completely abolished during storage, the antimutagenicity seen in peripheral blood was maintained with high statistical significance (Tables 1 and 2 ), indicating that the antimutagenic effects in bone marrow and peripheral blood are exerted by different active compounds differing in mode of action and exhibiting a very different chemical stability. The result also shows that the aqueous extracts have several bioactive compounds acting together at different levels to reduce the induced mutagenesis. Several studies have postulated that the stability factor plays a critical role for exerting biological actions. 12, 13 The MNT in peripheral blood can be conducted without sacrificing the animals. Therefore, an investigation of potential cell cycling alterations is possible by monitoring for several days after exposure to a clastogenic agent ( Table 2) . The results showed that the antimutagenic effect of L. edodes in blood is not due to an influence on normal cell cycling of the erythroid lineage in bone marrow since there was no delay or acceleration related to the maximum response of MNRET in the blood stream in treated groups when compared to the positive control. A comparison between groups treated with dosages of 5 or 10 mg/day showed that an increase in the L. edodes dose did not cause any significant impact on antimutagenicity ( Table 2 ), indicating that the optimum dose is achieved at £ 5 mg/day, with higher concentrations of the bioactive compounds (10 mg/ day) having no additional effect on MNRET.
We also investigated the general numbers of circulating hematopoietic cells based on the possibility that L. edodes treatment modulates the number of circulating red blood cells, causing a relative increase in blood stream RETs, which could give the impression of a reduction in MNRET (Table 3 ). In general, our results indicated that the number of hematopoietic red blood cells determined in treated groups was not statistically different from nontreated rodents. However, there was a significant increase in the relative number of monocytes observed in blood smears. Our data are in accord with a previous report that lentinan, a polysaccharide obtained from L. edodes, increases monocytes in peripheral blood as well as granulocyte progenitor (colonyforming unit-granulocyte macrophage [CFU-GM]) cells in the spleen and bone marrow.
14 Since some of the actions exerted by this isolated polysaccharide have also been found in experiments using L. edodes fruiting bodies, 15, 16 we suppose that the aqueous extract used in this study could have acted in a manner similar to that of lentinan, increasing blood stream monocytes and possibly granulocyte progenitors (CFU-GMs). In fact, although we do not know the chemical composition of L. edodes aqueous extract, it had been demonstrated that aqueous extracts of several mushrooms contain a high concentration of polysaccharides, which could be responsible for the bioactive effects. [17] [18] [19] Monocytes have an intravascular life span of 1-3 days, leaving the blood stream at random and transforming into macrophages. Macrophages are phagocytes and function to remove foreign bodies, parasites, and bacteria. 20 Thus, if we look at the results in Table 3 from this perspective, we could suppose that the reduction in MNRETs in peripheral blood can be due to the enhanced phagocytic activity in the spleen. Blood filtration is the best known and a very important function of the spleen. Elements removed from circulation include aging cells and intraerythrocytic inclusions. The removal of aging or abnormal red blood cells by the spleen occurs within the cords of Billroth and is known as culling, 21, 22 whose molecular mechanism is still under investigation. However, it is generally agreed that cells bound for destruction become trapped, or perhaps held, within the reticulum meshwork of the spleen cords, and as their splenic transit time increases, they succumb to phagocytosis by resident macrophages. In addition to culling, the spleen also functions to remove intraerythrocytic inclusions (micronucleus and intraerythrocytic parasites such as Plasmodium falciparum) from circulating red cells. The ability of the spleen to clear these inclusions, while maintaining the integrity of the red cell itself is known as pitting and is an exclusive function of splenic tissue. Pitting occurs as cells within the cords attempt to reenter the circulation through the splenic sinuses. To do this, they must pass through slit-like fenestrations of the sinus endothelium. As this occurs, the deformable portion of the cell bends to negotiate the opening, whereas the inclusion, which is nondeformable, is unable to pass through the narrow passage; thus, it is left behind to be phagocytized by resident macrophages. [23] [24] [25] The above considerations led us to adapt the protocol developed by Hayashi et al. 6 to measure the spleen phagocytic activity. Our results support the view that the antimutagenic action toward MNRET in peripheral blood can be modulated largely by the splenic phagocytic activity (Table  4) , which is equally increased with L. edodes treatment both at 6 and 12 h (P < .001) after micronucleus induction by CP. This intense activity in the first 12 h explains why the reduction in the frequency of MNRET was almost maximum 24 h after the induction of mutations (Table 2) . Figures 2 and  3 show that even though the spleen phagocytic activity was greatly increased by L. edodes treatment, the production of H 2 O 2 and NO from macrophages of mice treated with L. edodes extract was comparable to the control values. Thus, the results suggest that the increased clearance function of the spleen was probably due to the higher number of macrophages and not due to the enhanced activation state of individual cells.
The understanding that L. edodes blood antimutagenicity related to reduction in MNRET was produced by specific enhancement of spleen phagocytosis helps to amplify the overall picture and suggests that this specific action could be better evaluated by using different experimental models to determine whether it could be applied in some way, for example, as an adjuvant or in a prophylactic manner to reduce the body parasite burden in infectious diseases involving intraerythrocytic parasites, such as in malaria. However, further studies are necessary before L. edodes can be used in the prophylaxis treatment of infectious parasitic diseases, which are very frequent in developing countries such as Brazil.
Finally, this study points out that clarifying the mode of actions of L. edodes using in vivo models to elucidate the underlying events of the observed effect is important since it can unexpectedly open up practical applications in different areas.
